Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Рак мочевого пузыря

Литература

  1. Болотина Л.В. Химиотерапия распространенного рака мочевого пузыря: дис. … канд. мед. наук. М., 2002.

  1. Воробьев А.В. Классификация и диагностика рака мочевого пузыря, вопросы дифференциальной диагностики. Практическая онкология. 2003; 4 (4): 200–201.
  2. Злокачественные новообразования в России в 2014 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016.
  3. Коган М.И., Перепечай В.А. Современная диагностика и хирургия рака мочевого пузыря. Ростов-на-Дону, 2002.
  4. Лекции цикла «Онкоурология». Сост. И.Н. Денисов, А.Д. Каприн. М., 2008.
  5. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Pак мочевого пузыря. М., 2001.
  6. Митина Л.А., Казакевич В.И., Степанов С.О. Ультразвуковая онкоурология. Под ред. В.И. Чиссова, И.Г. Русакова. М.: Медиа Сфера, 2005. 200 с.
  7. Перепечай В.А. Обоснование ортотопической сигмопластики для восстановления мочевого пузыря: Дис. … канд. мед. наук. Ростов-на-Дону, 2000.
  8. Сергеева Н.С., Маршутина Н.В. Новые серологические и уринологические опухолевые маркеры в уточняющей диагностике и мониторинге онкологических больных. Материалы VII Российской онкологической конференции. М., 2003.
  9. Camey M., Botto H. The ileal neobladder: development and long-term experi- ence, Carney I and II. Scand. J. Urol. Nephrol. (Suppl.). 1992; 142: 98–100.
  10. Теплов А.А. Хирургическое и комплексное лечение больных раком мочевого пузыря: дис. … д-ра мед. наук. М., 2006.
  11. Теплов А.А. Хирургическое и комплексное лечение больных инвазивным раком мочевого пузыря. Состояние проблемы. Выбор лечебной тактики. Материалы Международного научного форума «Онкология на рубеже XXI века. Возможности и перспективы». М., 1999. С. 382–383.
  12. Урология: иллюстрированное руководство. От симптомов к диагнозу и лечению. Под ред. П.В. Глыбочко, Ю.Г. Аляева, Н.А. Григорьева. М.: ГЭ- ОТАР-Медиа, 2014.
  13. Урология. Под ред. П.В. Глыбочко, Ю.Г. Аляева. Ростов-на-Дону: Феникс, 2014.
  14. Хинман Ф. Оперативная урология. М., 2003.
  15. Чиссов В.И., Соколов В.В., Булгакова Н.Н., Филоненко Е.В. Флюоресцентная эндоскопия, дермаскопия, спектрофотометрия в диагностике злокачественных опухолей основных локализаций. Российский биотерапевтический журнал. 2003; 4 (2): 45–56.
  16. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant cisplatin for advanced bladder cancer. In: The Cochrane Library 2, 2004. Chichester, UK: John Wiley.
  17. Bajorin D.F. Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced blad- der cancer. J. Clin. Oncol. 2001; 19: 17S.

  1. Boffetta P., Silverman D.T. A metaanalysis of bladder cancer and diesel exhaust exposure. Epidemiology. 2001; 12: 125.
  2. Bohle A., Brandau S. Immune mechanisms in bacillus Calmette – Guerin im- munotherapy for superficial bladder cancer. J. Urol. 2003; 170: 964.
  3. Bono A.V., Benvenuti C., Reali L. et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog. Clin. Biol. Res. 1989; 303: 533.
  4. Brennan P., Bogillot O., Cordier S. et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int. J. Cancer. 2000; 86: 289.
  5. Campbell’s Urology. Eds. P.C. Walsh et al. 8th edn. Philadelphia, 2002; 1–4.
  6. Castelao J.E., Yuan J.M., Skipper P.L. et al. Gender- and smoking-related bladder cancer risk. J. Natl. Cancer. Inst. 2001; 93: 538.
  7. Cole C.J., Pollack A., Zagars G.K. et al. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int. J. Radiat. Oncol. Biol. Phys. 1995; 32: 331.
  8. Cole P., Hoover R., Friedell G.H. Occupation and cancer of the lower urinary tract. Cancer. 1972; 29: 1250.
  9. Cookson M.S., Chang S.S., Wells N., Parekh D.J. Complications of radical cystec- tomy for nonmuscle invasive disease: comparison with muscle invasive disease. J. Urol. 2003; 169: 101.
  10. Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: A pro- spective randomized clinical trial. Proc. Am. Soc. Clin. Oncol. 1995; 14: 237.
  11. Datta S.N., Allen G.M., Evans R. et al. Urinary tract ultrasonography in the evaluation of haematuria: A report of over 1,000 cases. Ann. R. Coll. Surg. Eng. 2002; 84: 203.
  12. De Neve W., Lybeert M.L., Goor C. et al. Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time. Radiother. Oncol. 1995; 36: 183.
  13. Delnay K.M., Stonehill W.H., Goldman H. et al. Bladder histological changes associated with chronic indwelling urinary catheter. J. Urol. 1999; 161: 1106.
  14. Donat M.D., Herr H.W. Transitional cell carcinoma of the renal pelvis and ure- ter: diagnosis, staging, management, and prognosis. In: Urologic Oncology. Eds. J.E. Osterling, J.P. Richie. Philadelphia: WB Saunders Harcourt Brace & Co, 1997. P. 215.
  15. Elmajian D.A., Stein J.P., Esrig D. et al. The Kock ileal neobladder: updated ex- perience in 295 male patients. J. Urol. 1996; 156 (3): 920–925.
  16. Freiha F., Reese J., Torti F. A randomized trial of radical cystectomy versus radi- cal cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle-invasive bladder cancer. J. Urol. 1996; 155: 495.
  17. Gospodarowicz M.K., Quilty P.M., Scalliet P. et al. The place of radiation therapy as definitive treatment of bladder cancer. Int. J. Urol. 1995; 2 (Suppl. 2): 41.
  18. Grossman H.B., Natale R.B., Tangen C.M. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Eng. J. Med. 2003; 349: 859.
  19. Guidelines. European Association of Urology. 2007.
  20. Hall R.R. Updated results of a randomised controlled trial of neoadjuvant cis- platin, methotrexate, and vinblastine chemotherapy for muscle-invasive blad- der cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: 178.
  21. Herr H.W. Routine CT scan in cystectomy patients: does it change manage- ment? Urology. 1996; 47: 324.
  22. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics. CA Cancer. J. Clin. 2002; 52: 23.
  23. Jenkins B.J., Caulfield M.J., Fowler C.G. et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive bladder can- cer. Br. J. Urol. 1988; 62: 343.
  24. Jung I., Messing E. Molecular mechanisms and pathways in bladder cancer de- velopment and progression. Cancer Control. 2000; 7: 325.
  25. Kaufman D., Raghavan D., Carducci M. et al. Phase II trial of gemcitabine plus cis- platin in patients with metastatic urothelial cancer. J. Clin. Oncol. 2000; 18: 1921.
  26. Khadra M.H., Pickard R.S., Charlton M. et al. A prospective analysis of 1,930 pa- tients with hematuria to evaluate current diagnostic practice. J. Urol. 2000; 163: 524.
  27. Lerner S.P., Skinner D.G. Radical cystectomy for bladder cancer. Comprehen- sive textbook of genitourinary oncology. Baltimore: Williams and Wilkins, 1996. P. 442–463.
  28. Light J.K., Engelmann U.H. Le bag: total replacement of the bladder using an ileocolonic pouch. J. Urol. 1986; 135: 27–31.
  29. Loehrer P., Einhorn L.H., Elson P.J. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in pa- tients with metastatic urothelial carcinoma: A Cooperative Group Study. J. Clin. Oncol. 1992; 10: 1066.
  30. Logothetis C.J., Dexeus F., Sella A. et al. A prospective randomized trial compar- ing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J. Clin. Oncol. 1990; 8: 1050.
  31. Logsetty S. Screening for bladder cancer. In: Canadian Task Force on the Peri- odic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada, 1994. P. 826–836.
  32. Lutzeyer W., Rubben H., Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J. Urol. 1982; 127: 250.
  33. Mameghan H., Fisher R., Mameghan J. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int. J. Ra- diat. Oncol. Biol. Phys. 1995; 31: 247.
  34. Matsui U., Topoll B., Miller K., Hautmann R.E. Metabolic long-term follow up of the ideal neobladder. Eur. Urol. 1993; 24 (2): 197–200.
  35. McDougal W.S. Use of intestinal segments and urinary diversion. In: P.C. Walsh, A.B. Retik, E.D. Vaughan et al. (eds.) Campbell’s Urology. Vol. 3. 7th edn. Phila- delphia, Pa: W.B. Saunders, 1997. P. 3121–3161.
  36. Mohr D.N. et al. Asymptomatic microhematuria and urologic disease. A popu- lation-based study. JAMA. 1986; 256: 224.
  37. Moore M.J., Winquist E.W., Murray N. et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1999; 17: 2876.
  38. Nakamura I. Postoperative care of neobladder using a detubularized intestinal segment. Hinyokika Kiyo. 1995; 41 (11): 441–541.
  39. Pfister C., Chautard D., Devonec M. et al. Immunocyt test improves the diagnos- tic accuracy of urinary cytology: results of a French multicenter study. J. Urol. 2003; 169: 921.
  40. Piper J.M., Tonascia J., Matanoski G.M. Heavy phenacetin use and bladder can- cer in women aged 20 to 49 years. N. Engl. J. Med. 1985; 313: 292.
  41. Pollack A., Zagars G.Z. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin. Urol. Oncol. 1996; 14: 86.
  42. Prescott S., Jackson A.M., Hawkyard S.J. et al. Mechanisms of action of intra- vesical bacille Calmette – Guerin: local immune mechanisms. Clin. Infect. Dis. 2000; 31 (Suppl. 3) : 91.
  43. Saxman S., Propert K., Einhorn L. et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vin- blastine and doxorubicin in patients with metastaic urothelial cancer: A Coop- erative Group Study. J. Clin. Oncol. 1997; 15: 2564.
  44. Schatte E., Grunenfelder J., Fradet Y., Miles B.J. Epidemiology of bladder cancer. In: Comprehensive Textbook of Genitourinary Oncology. N.J. Vogelzang, P.T. Scardino, W.U. Shipley, D.S. Coffey (eds.). Lippincott, Williams, and Wilkins, Philadelphia, 2000. P. 283.
  45. Sella A., Dexeus F.H., Chong C. et al. Radiation therapy associated invasive blad- der tumors. Urology. 1989; 33: 185.
  46. Shelley M.D., Court J.B., Kynaston H. et al. Intravesical bacillus Calmette – Guerin in Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews. 2000. CD001986.
  47. Skinner D.G., Daniels J.R., Russell C.A. et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J. Urol. 1991; 145: 459.
  48. Solsona E., Iborra I., Ricos J.V. et al. Effectiveness of a single immediate mito- mycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J. Urol. 1999; 161: 1120.
  49. Splinter T.A., Scher H.I., Denis L. et al. The prognostic value of the pathologi- cal response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J. Urol. 1992; 147: 606.
  50. Stadler W. Molecular events in the initiation and progression of bladder cancer. Int. J. Oncol. 1993; 3: 549.
  51. Stein J.P., Lieskovsky G., Cote R. et al. Radical cystectomy in the treatment of in- vasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 2001; 19: 666.
  52. Stockle M., Meyenburg W., Wellek S. et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 1992; 148: 302.
  53. Studer U., Bacchi M., Biederman C. et al. Adjuvant cisplatin chemotherapy fol- lowing cystectomy for bladder cancer. Results of a prospective randomized trial. J. Urol. 1994; 152: 81.
  54. Talar-Williams C., Hijazi Y.M., Walther M.M. et al. Cyclophosphamide induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. In- tern. Med. 1996; 124: 477.
  55. Tekes A., Kamel I., Imam K. et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR. 2005; 184: 121–127.
  56. Travis L.B., Curtis R.E., Glimelius B. et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J. Natl. Cancer. Inst. 1995; 87: 524.
  57. U. S. Preventive Services Task Force. Screening for Bladder Cancer in Adults: Recommendation Statement. June 2004. Agency for Healthcare Research and Quality. Rockville, MD, 2004.
  58. Vale C. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis. Lancet. 2003; 361: 1927.
  59. von der Maase H., Hansen S.W., Robeerts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multi- center, phase III study. J. Clin. Oncol. 2000; 18: 3068.
  60. Wright W. Geographical distribution of schistosomes and their intermediate hosts. In: Epidemiology and control of schistosomiasis (bilharziasis). N. Ansari (ed.). Karger S., Basel, 1973. P. 32.
  61. Yaman O., Baltaci S., Arikan N. et al. Staging with computed tomography, tran- srectal ultrasonography and transurethral resection of bladder tumour: com- parison with final pathological stage in invasive bladder carcinoma. Br. J. Urol. 1996; 78 (2): 197–200.
  62. http://uroweb.org/fi leadmin/guidelines/Guidelines 2016.pdf.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

Литература
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Оглавление

Данный блок поддерживает скрол*